Lannett Secures US Distribution Rights for Generic Version of COPD Drug Advair Diskus
10/1/19, 4:38 AM 07:38 AM EDT, 10/01/2019 (MT Newswires) -- Lannett Co. (LCI) said Tuesday it has secured exclusive distribution rights for the generic equivalent of Advair Diskus of Respirent Pharmaceuticals.
Under the deal, the company will commence distribution after approval of the US Food and Drug Administration, and will make an upfront payment, as well as future milestone payments and a portion of the net profits. The deal has a term of 10 years.
The company expects the product filing to be submitted with the FDA in the second half of its current fiscal year.
Advair Diskus is a treatment for chronic obstructive pulmonary disease and is a trademark of GlaxoSmithKline (GSK).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.